Depression: a neglected major illness
- PMID: 8270584
Depression: a neglected major illness
Abstract
Background: To illustrate the burden depression imposes on society, we present estimates of the annual costs of depression--$44 billion--as well as the number of individuals it affects per year--almost 11 million. Although these estimates point to depression as a major illness, this study examines why it is not generally considered as such by the medical and public health communities or by society at large.
Method: We develop a framework that compares depression with major illnesses such as coronary heart disease, cancer, and AIDS by highlighting salient characteristics of each illness. This comparative illness framework considers the costs, prevalence, distribution of sufferers, mortality, recognition, and treatability of each disease. This comparison underscores many of the similarities and differences among the illnesses examined.
Results: Because depression often is not properly recognized and begins to affect many people at a relatively early age, it exacts costs over a longer period of time and in a more subtle manner than other major illnesses. It also imposes a particularly heavy burden on employers in the form of higher workplace costs.
Conclusion: We conclude that, because of the potential for successful treatment, increased attempts to reach untreated sufferers of depression appear to be warranted. Employers as a group have a particular incentive to invest in the recognition and treatment of this widespread problem, in order to reduce the substantial costs it imposes upon them each year.
Comment in
-
The costs of treating depression.J Clin Psychiatry. 1993 Nov;54(11):425-6. J Clin Psychiatry. 1993. PMID: 8270585 No abstract available.
Similar articles
-
The economic burden of depression in 1990.J Clin Psychiatry. 1993 Nov;54(11):405-18. J Clin Psychiatry. 1993. PMID: 8270583
-
Cost of depression in Europe.J Ment Health Policy Econ. 2006 Jun;9(2):87-98. J Ment Health Policy Econ. 2006. PMID: 17007486
-
The economic burden of depression with painful symptoms.J Clin Psychiatry. 2003;64 Suppl 7:17-23. J Clin Psychiatry. 2003. PMID: 12755648 Review.
-
Costs of nine common mental disorders: implications for curative and preventive psychiatry.J Ment Health Policy Econ. 2006 Dec;9(4):193-200. J Ment Health Policy Econ. 2006. PMID: 17200596
-
The burden of disease for treatment-resistant depression.J Clin Psychiatry. 2001;62 Suppl 16:26-31. J Clin Psychiatry. 2001. PMID: 11480881 Review.
Cited by
-
Mirtazapine. A pharmacoeconomic review of its use in depression.Pharmacoeconomics. 2000 May;17(5):515-34. doi: 10.2165/00019053-200017050-00008. Pharmacoeconomics. 2000. PMID: 10977391 Review.
-
Searching the cytochrome p450 enzymes for the metabolism of meranzin hydrate: a prospective antidepressant originating from Chaihu-Shugan-San.PLoS One. 2014 Nov 26;9(11):e113819. doi: 10.1371/journal.pone.0113819. eCollection 2014. PLoS One. 2014. PMID: 25427198 Free PMC article.
-
Sertraline. A pharmacoeconomic evaluation of its use in depression.Pharmacoeconomics. 1996 Oct;10(4):409-31. doi: 10.2165/00019053-199610040-00009. Pharmacoeconomics. 1996. PMID: 10184609 Review.
-
Collaboration Between Mental Health Services and Primary Care: The Bologna Project.Prim Care Companion J Clin Psychiatry. 1999 Dec;1(6):180-183. doi: 10.4088/pcc.v01n0602. Prim Care Companion J Clin Psychiatry. 1999. PMID: 15014669 Free PMC article.
-
Brief cognitive behavioral therapy compared to general practitioners care for depression in primary care: a randomized trial.Trials. 2010 Oct 12;11:96. doi: 10.1186/1745-6215-11-96. Trials. 2010. PMID: 20939917 Free PMC article. Clinical Trial.